New mRNA flu shot passes first safety test in humans
NCT ID NCT05446740
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental mRNA-based flu vaccine in 324 healthy younger (18-45) and older (60-80) adults. The main goal was to check safety and how well the vaccine triggers an immune response. Participants received one of several dose levels or a placebo, and researchers monitored side effects and antibody levels for about two months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-based influenza vaccine (GSK4382276A)
What this could lead to
If successful, this could lead to a new, more effective flu vaccine that uses mRNA technology, potentially offering better protection against influenza.
What could go wrong
This is an early Phase 1 trial with only 324 participants, so safety and immune response are still being tested. The vaccine may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Edegem, 2650, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Halifax, Nova Scotia, B3J 3G9, Canada
-
GSK Investigational Site
Sherbrooke, Quebec, J1L 0H8, Canada
-
GSK Investigational Site
Madrid, 28006, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28222, Spain